These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 17699221

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 4. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
    Arenas MD, Alvarez-Ude F, Gil MT, Moledous A, Malek T, Nuñez C, Devesa R, Carretón MA, Soriano A.
    Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism.
    Messa P, Macário F, Yaqoob M, Bouman K, Braun J, von Albertini B, Brink H, Maduell F, Graf H, Frazão JM, Bos WJ, Torregrosa V, Saha H, Reichel H, Wilkie M, Zani VJ, Molemans B, Carter D, Locatelli F.
    Clin J Am Soc Nephrol; 2008 Jan; 3(1):36-45. PubMed ID: 18178780
    [Abstract] [Full Text] [Related]

  • 7. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients.
    Shireman TI, Almehmi A, Wetmore JB, Lu J, Pregenzer M, Quarles LD.
    Am J Kidney Dis; 2010 Dec; 56(6):1108-16. PubMed ID: 20951487
    [Abstract] [Full Text] [Related]

  • 8. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU.
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [Abstract] [Full Text] [Related]

  • 9. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
    Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW.
    J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
    [Abstract] [Full Text] [Related]

  • 10. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results.
    Fishbane S, Shapiro WB, Corry DB, Vicks SL, Roppolo M, Rappaport K, Ling X, Goodman WG, Turner S, Charytan C.
    Clin J Am Soc Nephrol; 2008 Nov; 3(6):1718-25. PubMed ID: 18945995
    [Abstract] [Full Text] [Related]

  • 11. Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.
    Greenbaum LA, Benador N, Goldstein SL, Paredes A, Melnick JZ, Mattingly S, Amdahl M, Williams LA, Salusky IB.
    Am J Kidney Dis; 2007 Jun; 49(6):814-23. PubMed ID: 17533024
    [Abstract] [Full Text] [Related]

  • 12. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience.
    Lucchi L, Carboni C, Stipo L, Malaguti V, Ferrari F, Graziani R, Arletti S, Graziosi C.
    Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793
    [Abstract] [Full Text] [Related]

  • 13. Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients.
    El-Shafey EM, Alsahow AE, Alsaran K, Sabry AA, Atia M.
    Ther Apher Dial; 2011 Dec; 15(6):547-55. PubMed ID: 22107691
    [Abstract] [Full Text] [Related]

  • 14. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism.
    Henley C, Colloton M, Cattley RC, Shatzen E, Towler DA, Lacey D, Martin D.
    Nephrol Dial Transplant; 2005 Jul; 20(7):1370-7. PubMed ID: 15855208
    [Abstract] [Full Text] [Related]

  • 15. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
    Moe SM, Cunningham J, Bommer J, Adler S, Rosansky SJ, Urena-Torres P, Albizem MB, Guo MD, Zani VJ, Goodman WG, Sprague SM.
    Nephrol Dial Transplant; 2005 Oct; 20(10):2186-93. PubMed ID: 16030053
    [Abstract] [Full Text] [Related]

  • 16. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
    Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drüeke TB, Goodman WG.
    N Engl J Med; 2004 Apr 08; 350(15):1516-25. PubMed ID: 15071126
    [Abstract] [Full Text] [Related]

  • 17. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis.
    Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Floege J, ADVANCE Study Group.
    Nephrol Dial Transplant; 2011 Apr 08; 26(4):1327-39. PubMed ID: 21148030
    [Abstract] [Full Text] [Related]

  • 18. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?
    Shahapuni I, Mansour J, Harbouche L, Maouad B, Benyahia M, Rahmouni K, Oprisiu R, Bonne JF, Monge M, El Esper N, Presne C, Moriniere P, Choukroun G, Fournier A.
    Semin Dial; 2005 Apr 08; 18(3):226-38. PubMed ID: 15934970
    [Abstract] [Full Text] [Related]

  • 19. Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study.
    Roggeri DP, Mazzaferro S, Brancaccio D, Cannella G, Messa P, Di Luca M, Morosetti M, Costanzo AM, di Luzio Paparatti U, Cornago D, Cozzolino M, FARO Study Group.
    J Med Econ; 2012 Apr 08; 15(6):1110-7. PubMed ID: 22702445
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.